Sino Biopharmaceutical (HK:1177) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sino Biopharmaceutical has entered into a global collaboration with Biosion and Aclaris Therapeutics to develop an anti-TSLP monoclonal antibody, BSI-045B. Aclaris will pay over $40 million in cash and 19.9% in common stock to Sino Biopharmaceutical, alongside potential regulatory and sales milestone payments exceeding $900 million. This strategic partnership aims to advance treatments for conditions such as asthma and atopic dermatitis.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
